# KEYNOTE-010 (NCT01905657)

> Study of Two Doses of Pembrolizumab (MK-3475) Versus Docetaxel in Previously Treated Participants With Non-Small Cell Lung Cancer (MK-3475-010/KEYNOTE-010)

No report yet. It can be ordered.

- Drugs tested: pembrolizumab
- Indication: previously treated PD-L1-positive advanced non-small-cell lung cancer

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT01905657
- Phase: PHASE2, PHASE3
- Status: COMPLETED
- Sponsor: Merck Sharp & Dohme LLC
- Conditions: Non Small Cell Lung Cancer (NSCLC)
- Interventions: Pembrolizumab; Docetaxel
- Enrollment: 1034
- Primary outcome: Overall Survival (OS)
- Primary outcome: Progression-free Survival (PFS) by Response Evaluation Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
- Primary outcome: Percentage of Participants Experiencing Adverse Events (AEs)
- Primary outcome: Percentage of Participants Discontinuing Study Drug Due to AEs

## Indexed commentary on KEYNOTE-010 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6
- Podcasts: 4
- YouTube: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=keynote-010-nct01905657

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT01905657", "email": "<work email>"}; the inbox owner confirms by the emailed link.